All In Biotech

Drug Trial Radar · NCT07461220

Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy

A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants With Parkinson's Disease and Apathy

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Feb 18, 2026

Primary completion

May 2027

Study completion May 2027

Sponsor

Sponsor type
Industry
Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
First posted
Mar 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial's goal is to evaluate if the IRL757 is safe and has a good tolerability in participants with Parkinson's disease and experiencing apathy (a lack of interest or motivation). In addition, the trial is aiming to learn if IRL757 has effects on the symptoms of Parkinson's disease. Researchers will compare the effects of IRL757 to a placebo (a look-alike substance that contains no drug). Participants who fit the study criteria will be treated with the study drug (either the active drug IRL757 or placebo) for 12 weeks and will visit the clinic at 5 defined timepoints for check-ups and tests. A follow-up call after the end of treatment will be done 4 weeks after the last study drug intake.

Conditions

  • PARKINSON DISEASE (Disorder)
  • Apathy
  • Safety

Interventions

  • IRL757Drug

    IRL757 will be administered daily for 12 weeks. The study drug is available as capsules for oral administration.

  • PlaceboDrug

    The study drug is administered daily for 12 weeks. The placebo is available in form of capsules to be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of IRL757 after repeated daily dosing for 12 weeks in participants with PD who have moderate to severe symptoms of apathyTime frame: From enrollment [signature of informed consent form] to end of study [4 weeks after last study drug administration]
  2. To evaluate the safety and tolerability of IRL757 after repeated daily dosing for 12 weeks in participants with PD who have moderate to severe symptoms of apathyTime frame: From enrollment [signature of informed consent form] to end of study [4 weeks after last study drug administration]
  3. To evaluate the safety and tolerability of IRL757 after repeated daily dosing for 12 weeks in participants with PD who have moderate to severe symptoms of apathyTime frame: From enrollment [signature of informed consent form] to end of study [4 weeks after last study drug administration]

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • Medical Center "Galileo" OOD

    Pleven, Bulgaria · Recruiting

  • Medical Center Academica

    Pleven, Bulgaria · Recruiting

  • First University Multiprofile Hospital for Active Treatment MHAT - Neurology Clinic

    Sofia, Bulgaria · Recruiting

  • University Multiprofile Hospital for Active Treatment "Alexandrovska" EAD, Clinic of Neurological Diseases

    Sofia, Bulgaria · Recruiting

  • Neurologie Berlin

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Carl Gustav Carus

    Dresden, Germany · Withdrawn

  • Centrum Medyczne NEUROMED

    Bydgoszcz, Poland · Recruiting

  • Neuro-Care sp. z o.o. sp. Komandytowa

    Katowice, Poland · Recruiting

  • NeuroKlinika Prof. Andrzej Bogucki

    Lodz, Poland · Recruiting

  • EuroMedis Sp. z o.o.

    Szczecin, Poland · Recruiting

  • Centrum Medyczne NeuroProtect

    Warsaw, Poland · Recruiting

  • Hospital de la Santa Creu i Sant Pau, Unidad de trastornos del movimiento

    Barcelona, Spain · Recruiting

  • Hospital General Universitario de Elche

    Elche, Spain · Not yet recruiting

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.